# Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

> **NCT00244972** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 74 (actual)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Sorafenib Tosylate
- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT00244972
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244972, "Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00244972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*